Media Relations

Infinity Communications is a women-led agency based in Geneva, providing specialist expertise for commercial healthcare and global health sectors

Strategic collaboration further strengthens GHMC’s footprint and capabilities in key European market for biopharma and global health organizations

NEW YORK and GENEVA, February 17, 2025– Global Health Marketing & Communications (GHMC), the largest and most robust partnership of independent healthcare agencies worldwide, today announced the addition of Infinity Communications, a Swiss-based agency to its international network. This addition strengthens GHMC’s offerings in the European region and expands the capabilities of the network in this important market.

Established in 2019, Infinity Communications is a leading health communications agency operating in an influential market. Strategically placed at the intersection of commercial and public health, their multi-lingual, women-led team works with pharmaceutical, biotech, medtech, and non-profit organizations to create research-driven, strategic communications for a healthier world.

“Infinity Communications is a leader in the global healthcare communications space, delivering hugely impactful programming in Switzerland and around the world. We are thrilled to welcome Sarbjit and her team to the GHMC family, further enhancing our ability to serve our Global and European clients,” said GHMC President and Chief Growth Officer of Spectrum Science, Tim Goddard.

Switzerland is the global or regional headquarters to many of the world’s leading pharmaceutical and biotechnology companies, and a powerhouse of scientific and technological innovation. It is also home to the World Health Organization, and a number of other internationally recognized healthcare NGOs.

For Infinity, joining the GHMC network opens new opportunities. “It is an honor to represent the GHMC Network in Switzerland,” said Sarbjit Kunar, Founder and Managing Director of Infinity Communications. “We have come a long way these last five years and are proud to use our expertise to help GHMC partners localize their campaigns and give Swiss-based organizations the chance to extend their reach through unparalleled access to a global talent pool.”

As the exclusive partner in Switzerland, Infinity Communications will join six other European partner agencies including Aurora in United Kingdom, Berbés in Spain, GuessWhat in Portugal, MPR in Romania, fischerAppelt in Germany and Connexia in Italy who work closely to ensure regional programming meets the needs of in-market teams and audiences.

About Global Health Marketing & Communications (GHMC)

Established in 2001, GHMC is the largest and most robust partnership of independent healthcare agencies worldwide, dedicated to improving outcomes through the delivery of dynamic, health-driven experiences that result in meaningful global change. With an average member agency tenure of more than 10 years, the group consists of more than 700 health-specialist communications professionals spanning more than a dozen disciplines, from patient engagement to medical communications to advertising and clinical trial recruitment. The agencies that make up the partnership share a belief in insights-driven strategies and a commitment to collaboration. Today, GHMC has capabilities and reach into more than 60 countries. For more information, visit GHMCNetwork.com or follow us on X and LinkedIn.   

About Infinity Communications

Infinity Communications is a women-led healthcare communications agency with a global reach. Established in 2019 and based in Geneva — a hub for scientific innovation and global health leadership — we work with pharmaceutical, biotech, medtech, and non-profit organisations to create research-driven, strategic communications for a healthier world. Bringing a unique understanding of commercial healthcare and global health landscapes, our multi-lingual team combines deep scientific expertise with creative and strategic skillsets. Together we have delivered on a range of projects that have worked for audiences including patients, healthcare providers, government representatives and high-level policy makers.  

By Chris Bath, Managing Director at Aurora Healthcare Communications

The world is in shock.

Pandemic ‘recovery’; cost of living crisis; rising inflation and geopolitical instability at an all-time high for a generation. We’re in the middle of a polycrisis, and that’s not all.

Around 1.5 billion people will be going to the polls this year, as significant elections are taking place in more than 50 countries which between them hold almost half of the world’s population. 

Uncertainty, then, is a constant we have come to live with. The result of this, is that we have come to crave something many people shy away from: change.

Global change coming to life science is good for all.

The life science industry, often proving to be resistant to most existential crises and pressure, has faced unprecedented low levels of investment, M&A activity and, as a result, lagging clinical pipelines. 2023 saw the lowest number of clinical trial starts since 2018.

If the world is in shock, the industry needs a shock of its own to ignite the change that innovation needs. This change is round the corner.

‘Pipeline in a product’ therapeutics, along with new and complex modalities, that will transform medicine, and, if given the right access environment, will also necessitate a reset, or change, in how we treat disease. Countries are rapidly standing up modern health systems that can accommodate these new innovations (let’s park capacity for a second, because that’s an altogether different challenge) and this rapid expansion requires genuine global expertise.

According to Deloitte, one of the main reasons why larger biopharma organisations miss their growth targets is because of an inadequate understanding of market dynamics and a complete misunderstanding of customer needs. A shameful finding given the hyperconnected world we live in. In today’s world, there really is no excuse, and change is not being embraced to stay in sync with the world today.

A true worldview and ‘global’ expertise then are paramount. But there really is no such thing as ‘global’ when it comes to life sciences. With every border comes a new culture to embrace, a new set of compliance considerations to consider and a new health system to navigate. The reality is that our work needs to resonate with countries and regions far more diverse than the term ‘Global’ allows.

For global strategy to be a success, you need to think ‘Glocally.’

Overcoming tunnel vision by thinking ‘Glocal’

How we tell stories about breakthrough science and the value this delivers to countries with unmet needs, demands a worldview on a range of issues to make sure medicine gets into the hands of those who need it.

Recent changes to EU regulations (for example, the Clinical Trial Regulation and new Medical Device/IVD Regulation) and other market uncertainties, such as cross-border collaborations and their potential impact on market access, are making it increasingly difficult for biopharma and biotech to forge ahead.

For programmes to resonate (and results to follow), multiculture, diversity and the need to consider all stakeholders in the care pathway are important, and that requires more than just a local presence, it necessitates a true understanding of local market dynamics. That means:

  • Ensuring clinical trial recruitment materials are trans-created, so they not only resonate in-market, but also, they engage sites and recruit patients, and protocols co-designed with patient experience data.
  • Commercial strategies are built with worldwide insight, supporting activities designed to drive uptake of medicines and new technologies through creative-led medical communications.
  • Market access plans need to be shaped with payors years in advance of a commercial launch, and the right data generated through clinical development programs to gain reimbursement.
  • Building global integrated teams that deliver across time zones to deliver at pace with cultural and compliance understanding built in.

As innovation lays a path for companies to expand internationally, we need to re-calibrate our understanding of the needs of nations and regions and people in a way that demands genuine expertise.

Our clients need partners who understand all these challenges, and in fact are purposefully designed to address and embrace them. So, that’s what we’ve built.

A Global vision with local precision

With decades of experience across every region of the globe, we’ve witnessed firsthand how the nuances of local geographies and cultures influence each phase of drug development and commercialisation. These insights have shaped our approach, leading us to create a platform of services that operate in harmony across the globe, delivering results that are truly greater than the sum of their parts.

By integrating solutions from clinical trial enrollment and medical communications to consulting and advertising, we’ve created an ability to take a wide-angle view, offering comprehensive, end-to-end support that spans the entire lifecycle—from early clinical milestones through to launch and global expansion.

This strategic offering is deeply ingrained in our heritage and our long-standing commitment to Global Health Marketing and Communications (GHMC)—the world’s largest network of independent healthcare agencies. Together, we’ve seen the difference a strategic and sensitive approach to multi-market programmes can make, as part of a deep understanding of healthcare across markets, cultures and codes.

As we seek to deliver change, we need to embrace it. And that’s what a truly ‘global’ partner like Spectrum Science is designed to do. If you want to see what this difference looks like, get in touch.

Over the past two weeks, the coronavirus that causes COVID-19 has been spreading like wildfire, with cases now rising faster outside of China than inside. The spread of the virus to more than 100 countries has presented new challenges for governments, health professionals and media covering the outbreak.

In case you missed it, access Part I, Part II, and Part III of our series, where GLOBALHealthPR leaders from the Asia-Pacific region, North America and Europe, and Latin America provide insights about the spread of information in their markets and the impact it has had locally.

In Part IV, we feature agency leaders from Italy, Spain, and the Nordics, who share their take on the impactful aspects, topics and evolution of this ongoing media conversation. Download the piece here.

Over the past two weeks, the COVID-19 outbreak has taken new twists and turns, with cases now rising faster outside of China than inside. The spread of the virus to more than 70 countries has presented new challenges for governments, health professionals and media covering the outbreak.

In case you missed it, access Part I and Part II of our series, where GLOBALHealthPR leaders from the Asia-Pacific region, North America and Europe provide insights about the spread of information in their markets and the impact it has had locally.

In Part III, we feature agency leaders from the Latin America region, who share their take on the impactful aspects, topics and evolution of this ongoing media conversation. Download the piece here.

Next, access Part IV, where we feature agency leaders from Italy, Spain, and the Nordics for their take.

GLOBALHealthPR has developed a series with local healthcare communications experts in countries where COVID-19 coronavirus cases have been confirmed.

In case you missed it, access Part I of our series where GLOBALHealthPR leaders from the Asia-Pacific region provide insights about the spread of information in their markets and the impact it has had locally.

In Part II, we feature agency leaders from North America and Europe, who share insights about the impactful aspects, topics and evolution of this ongoing media conversation. Download the piece here.

Next, access Part III and Part IV, where GLOBALHealthPR leaders from Latin America and Europe offer their insights.

GLOBALHealthPR partners worldwide collaborated to develop a series focused on the most impactful aspects, topics and evolution of media conversation surrounding the coronavirus outbreak. In this first installment, GLOBALHealthPR leaders from the Asia-Pacific region provide insights about the spread of information in their markets and the impact it has had locally. Download the full piece here.

 

Next, access Part II, Part III, and Part IV where we feature agency leaders from North America, Latin America, and Europe, who share insights about the impactful aspects, topics and evolution of this ongoing media conversation.